Association of Northern California Oncologists

http://www.anco.org/

 

ANCO’s ASCO Highlights 2019
H

ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Ribociclib/Endocrine Therapy & Improved PFS with Capivasertib + Fulvestrant

By ANCO’s ASCO Highlights 2019 FEATURING Helen K. Chew
By ANCO’s ASCO Highlights 2019 FEATURING Helen K. Chew
0 views
September 12, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Breast
15:19
ANCO’s ASCO Highlights 2019

ANCO's ASCO Update on HR+ Breast Cancer - Increased OS with Rib…

Feat. H. Chew
12:02
ANCO’s ASCO Highlights 2019

ANCO's ASCO Update on Breast Cancer - Margetuximab + Chemo Impr…

Feat. H. Chew